Functional compositions, tonics and uses having improved bone and joint health

Abstract

The application discloses a functional composition for improving bone and joint health, a conditioner and application. The functional composition comprises a first active component and a second active component; the first active component comprises elastin peptide, haematococcus pluvialis and ergothioneine; and the second active component comprises one or more of houttuynia cordata and non-denatured type II collagen. The application realizes the protection effect on joint, cartilage and bone health by scientific matching of the components and synergistically improving the glycosaminoglycan level in chondrocytes and the osteocalcin level in osteoblasts. Meanwhile, the components in the functional composition for improving bone and joint health are natural and have good biocompatibility, and have no obvious side effects, so that the application provides a kind of drug or a substitute for the treatment and prevention of bone diseases.

Description

Technical Field

[0001] This application relates to the field of biomedical technology, and in particular to functional compositions, conditioning agents and applications that improve bone and joint health. Background Technology

[0002] Bone and joint diseases are the most common orthopedic conditions, forming one of the three major orthopedic disciplines. These include bone and joint diseases, specifically conditions such as arthritis and bone loss. They are particularly prevalent in middle-aged and elderly individuals, and the symptoms often overlap. Clinical treatment primarily involves medication or interventions. While nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and diclofenac are the main choice for relieving joint pain and inflammation, their long-term use carries clear safety risks, including gastrointestinal damage, increased risk of cardiovascular events, and nephrotoxicity, necessitating the development of safer alternatives. In the field of nutritional supplements, their effectiveness is generally limited. Therefore, developing drugs, nutritional supplements, and functional foods with good efficacy, low side effects, and high safety is crucial for the current clinical treatment and intervention of bone and joint diseases. Summary of the Invention

[0003] Therefore, it is necessary to provide a functional composition that improves bone and joint health for the clinical treatment or prevention of bone diseases, with significant advantages of good efficacy, low side effects, and high safety.

[0004] In a first aspect, this application provides a functional composition for improving bone and joint health, the functional composition comprising a first active component and a second active component;

[0005] The first active component includes elastin peptide, Haematococcus pluvialis, and ergothioneine;

[0006] The second active component includes one or more of houttuynia cordata and non-denatured type II collagen.

[0007] In some embodiments, the first active component comprises, at a concentration of 1 μg / mL to 500 μg / mL of elastin peptide, 40 ng / mL to 20 μg / mL of Haematococcus pluvialis, and 40 ng / mL to 20 μg / mL of ergothioneine, in the functional composition for improving bone and joint health; and / or, at a concentration of 40 ng / mL to 20 μg / mL of houttuynia cordata, in the functional composition; and / or, at a concentration of 500 ng / mL to 250 μg / mL of undenatured type II collagen, in the functional composition.

[0008] In some embodiments, the second active component includes houttuynia cordata and non-denatured type II collagen.

[0009] In some embodiments, the functional composition comprises, at concentrations in the functional composition for improving bone and joint health, 100 μg / mL to 500 μg / mL of elastin peptides, 4 μg / mL to 20 μg / mL of Haematococcus pluvialis, 4 μg / mL to 20 μg / mL of ergothioneine, 4 μg / mL to 20 μg / mL of Houttuynia cordata, and 25 μg / mL to 250 μg / mL of non-denatured type II collagen.

[0010] In some embodiments, the functional composition having the effect of improving bone and joint health further includes a third active component;

[0011] The third active component includes one or more of hyaluronic acid and sodium hyaluronate;

[0012] The amount of the third active component added is 100 ng / mL to 50 μg / mL, based on the concentration in the functional composition for improving bone and joint health.

[0013] Secondly, this application also provides a class of conditioning agents, said conditioning agents comprising the functional compositions provided in the first aspect that improve bone and joint health.

[0014] In some embodiments, the conditioning agent is administered topically and / or orally; and / or, the dosage form of the conditioning agent includes suspensions, granules, capsules, powders, tablets, emulsions, solutions, pellets, injections, aerosols, gels, patches, dressings, drops, or liniments.

[0015] Thirdly, this application also provides the use of functional compositions or conditioning agents in the preparation of formulations for the treatment or prevention of bone diseases, wherein the functional compositions include the functional compositions provided in the first aspect that improve bone and joint health, and the conditioning agents include the conditioning agents provided in the second aspect.

[0016] In some embodiments, the skeletal disease includes bone disease and / or joint disease.

[0017] In some embodiments, the bone disease includes bone loss diseases; and / or, the joint disease includes osteoarthritis.

[0018] Compared with traditional technologies, the technical solution of this application has the following advantages:

[0019] This application provides a class of functional compositions for improving bone and joint health. The compositions include elastin peptides, Haematococcus pluvialis, and ergothioneine; and are formulated with one or more components of Houttuynia cordata and non-denatured type II collagen to synergistically promote the production of glycosaminoglycans in chondrocytes and osteocalcin in osteoblasts, thereby achieving therapeutic and preventative effects on bone diseases. Furthermore, the raw materials of the functional compositions for improving bone and joint health in this application are naturally derived, safe, and biocompatible. While achieving significant therapeutic and preventative effects on bone diseases, they have no obvious side effects, providing a class of drugs or alternatives for the treatment and prevention of bone diseases. Detailed Implementation

[0020] To facilitate understanding of the present invention, preferred embodiments are provided below to provide a more complete description of the invention. However, the present invention can be implemented in many different forms and is not limited to the embodiments described herein. Rather, these embodiments are provided to enable a thorough and complete understanding of the disclosure of the present invention.

[0021] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application belongs. The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the application.

[0022] As used herein, "optional," "optional," and "optional" refer to either "with" or "without" parallel options. If multiple "optional" entries appear in a technical solution, each "optional" entry is independent unless otherwise specified and there are no contradictions or mutual constraints. The term "and / or" as used herein includes any and all combinations of one or more related listed items. Unless otherwise specified, "multiple," "multiple," etc., as used herein refer to a quantity greater than 2 or equal to 2; for example, "one or more" indicates one, two, or more than two. In open-ended technical features or solutions described herein using words such as "containing," "including," and "comprising," unless otherwise specified, additional members beyond the listed members are not excluded. This can be considered as providing both a closed-ended feature or solution consisting of the listed members and an open-ended feature or solution that includes additional members beyond the listed members.

[0023] In this application, the terms "first aspect," "second aspect," "third aspect," "fourth aspect," etc., are used for descriptive purposes only and should not be construed as indicating or implying relative importance or quantity, nor should they be construed as implicitly indicating the importance or quantity of the indicated technical features. Moreover, "first," "second," "third," "fourth," etc., serve only as a non-exhaustive enumeration and should be understood not to constitute a closed limitation on quantity.

[0024] Unless otherwise specified, all embodiments and optional embodiments of this application can be combined to form new technical solutions.

[0025] Osteoarthritis and osteoarthritis are common bone diseases with high incidence rates and often intertwined, especially among the elderly, posing a significant and complex challenge to this population. Osteoarthritis primarily involves the degeneration of articular cartilage, while osteoporosis leads to the destruction of bone microstructure. Pathologically, they influence each other; the decline in bone biomechanical properties caused by osteoporosis exacerbates joint load imbalance, and joint inflammation can also disrupt bone metabolic homeostasis.

[0026] Glycosaminoglycans are the main structural components of the cartilage matrix framework, playing an irreplaceable supporting and protective role in joint function. Due to the large number of negative charges carried on their molecular chains, glycosaminoglycans possess strong hydrophilicity, capable of binding water molecules far exceeding their own weight to form a highly hydrated gel structure. This provides cartilage with excellent compressive elasticity, playing a crucial role in cushioning and shock absorption when the joint is subjected to mechanical loads. Simultaneously, glycosaminoglycans bind tightly to the type II collagen network, stabilizing the spatial conformation of collagen fibers through electrostatic repulsion, jointly resisting friction and impact during daily activities and preventing premature cartilage wear and degeneration. At the bioactivity level, glycosaminoglycans such as chondroitin sulfate can inhibit the release of key inflammatory pathways (such as NF-κB) and their mediated pro-inflammatory factors (such as IL-1β and TNF-α), thereby reducing synovial inflammation. They also provide important precursor substances for chondrocytes, supporting proteoglycan synthesis and promoting the self-renewal and repair of cartilage tissue.

[0027] Osteocalcin is a non-collagenous protein specifically synthesized by osteoblasts, playing a crucial role in maintaining bone health and mineralization. Its core function, as a vitamin K-dependent protein, after γ-carboxylation modification, allows it to bind with high affinity to calcium ions in hydroxyapatite, precisely guiding calcium deposition in the bone matrix and preventing pathological calcium deposition in blood vessel walls or soft tissues. This is essential for maintaining bone density and strength. Therefore, effectively activating osteocalcin is a key step in achieving high-quality bone mineralization and preventing osteoporosis.

[0028] However, current mainstream interventions employ drug therapy, such as nonsteroidal anti-inflammatory drugs (NSAIDs), which have significant safety concerns, including substantial side effects. Therefore, there is an urgent need to develop drugs or alternatives that are both safe and effective, such as nutritional supplements or functional foods.

[0029] This application aims to develop a functional composition that improves bone and joint health, with the advantages of good efficacy, low side effects, and safety.

[0030] In a first aspect, this application provides a functional composition for improving bone and joint health, the functional composition comprising a first active component and a second active component;

[0031] The first active component includes elastin peptide, Haematococcus pluvialis, and ergothioneine;

[0032] The second active component includes one or more of houttuynia cordata and non-denatured type II collagen.

[0033] This application utilizes a functional system to screen for a first active component comprising elastin peptides, Haematococcus pluvialis, and ergothioneine, and a second active component comprising one or more of broccoli water extract, mussels, and boron compounds. Through the scientific formulation of the first and second active substances, a synergistic effect is achieved, enabling the treatment and intervention of bone diseases and specifically protecting the health of joints and bones. Furthermore, many components in this functional composition for improving bone and joint health are of natural origin, exhibiting high safety. While providing excellent protection for joint and bone health, it has no significant side effects and is safer than traditional nonsteroidal anti-inflammatory drugs (NSAIDs). It can serve as an alternative or supplementary option to NSAIDs to enhance the protective effect on joints, cartilage, and bones.

[0034] In some embodiments, the first active component comprises, at a concentration of 1 μg / mL to 500 μg / mL of elastin peptide, 40 ng / mL to 20 μg / mL of Haematococcus pluvialis, and 40 ng / mL to 20 μg / mL of ergothioneine, in the functional composition having the effect of improving bone and joint health.

[0035] In some embodiments, the amount of Houttuynia cordata added, based on the concentration in the functional composition for improving bone and joint health, is 40 ng / mL to 20 μg / mL, including but not limited to 40 ng / mL, 100 ng / mL, 500 ng / mL, 1 μg / mL, 4 μg / mL, 6 μg / mL, 8 μg / mL, 10 μg / mL, 12 μg / mL, 14 μg / mL, 16 μg / mL, 18 μg / mL, 20 μg / mL, or any range formed by both of the foregoing and values ​​within such ranges. Further, based on the concentration in the functional composition for improving bone and joint health, the amount of Houttuynia cordata added is 4 μg / mL to 20 μg / mL.

[0036] In some embodiments, the amount of undenatured type II collagen added, based on the concentration in the functional composition for improving bone and joint health, is 500 ng / mL to 250 μg / mL, including but not limited to 500 ng / mL, 1 μg / mL, 5 μg / mL, 10 μg / mL, 15 μg / mL, 25 μg / mL, 50 μg / mL, 100 μg / mL, 125 μg / mL, 150 μg / mL, 200 μg / mL, 225 μg / mL, 250 μg / mL, or any combination thereof and values ​​within such ranges. Further, an addition of 25 μg / mL to 250 μg / mL of the undenatured type II collagen produces a better synergistic effect; even further, an addition of 200 μg / mL to 250 μg / mL of the undenatured type II collagen produces a better synergistic effect.

[0037] In some preferred embodiments, the first active component comprises, in concentrations in the functional composition having the effect of improving bone and joint health, 100 μg / mL to 500 μg / mL of elastin peptide, 4 μg / mL to 20 μg / mL of Haematococcus pluvialis, and 4 μg / mL to 20 μg / mL of ergothioneine.

[0038] In some preferred embodiments, the second active component includes houttuynia cordata and non-denatured type II collagen.

[0039] In some preferred embodiments, the functional composition for improving bone and joint health comprises, at concentrations of 1 μg / mL to 500 μg / mL elastin peptide, 40 ng / mL to 20 μg / mL Haematococcus pluvialis, 40 ng / mL to 20 μg / mL ergothioneine, 40 ng / mL to 20 μg / mL Houttuynia cordata, and 500 ng / mL to 250 μg / mL non-denatured type II collagen.

[0040] In some preferred embodiments, the composition of the functional composition for improving bone and joint health comprises, in concentrations thereof, 100 μg / mL-500 μg / mL of elastin peptide, 4 μg / mL-20 μg / mL of Haematococcus pluvialis, 4 μg / mL-20 μg / mL of ergothioneine, 4 μg / mL-20 μg / mL of Houttuynia cordata, and 25 μg / mL-250 μg / mL of non-denatured type II collagen.

[0041] In some preferred embodiments, the composition of the functional composition for improving bone and joint health comprises, in concentrations thereof, 100 μg / mL-500 μg / mL of elastin peptide, 4 μg / mL-20 μg / mL of Haematococcus pluvialis, 4 μg / mL-20 μg / mL of ergothioneine, 4 μg / mL-20 μg / mL of Houttuynia cordata, and 200 μg / mL-250 μg / mL of non-denatured type II collagen.

[0042] As a non-limiting example, the houttuynia cordata includes houttuynia cordata powder. It is understood that the houttuynia cordata powder is obtained by pulverizing houttuynia cordata raw material, or by pulverizing houttuynia cordata extract, which may be a water extract or an alcohol extract.

[0043] As a non-limiting example, the Haematococcus pluvialis includes one or more of Haematococcus pluvialis raw materials and their extracts. It is understood that the Haematococcus pluvialis raw material extracts include water extracts and / or alcohol extracts.

[0044] In some embodiments, the composition of the functional composition for improving bone and joint health further includes a third active component.

[0045] In some embodiments, the third active component includes one or more of hyaluronic acid and sodium hyaluronate. Furthermore, including sodium hyaluronate as the third active component can produce a better synergistic effect.

[0046] In some embodiments, the third active ingredient is added at a concentration of 100 ng / mL to 50 μg / mL, based on the concentration in the functional composition for improving bone and joint health, including but not limited to 100 ng / mL, 500 ng / mL, 1 μg / mL, 5 μg / mL, 10 μg / mL, 15 μg / mL, 20 μg / mL, 25 μg / mL, 30 μg / mL, 35 μg / mL, 40 μg / mL, 45 μg / mL, 50 μg / mL, or any combination thereof, and values ​​within such ranges. Furthermore, a third active ingredient added at a concentration of 5 μg / mL to 50 μg / mL produces a more superior synergistic effect.

[0047] In some preferred embodiments, the functional composition for improving bone and joint health comprises, at concentrations thereof, 100 μg / mL-500 μg / mL of elastin peptide, 4 μg / mL-20 μg / mL of Haematococcus pluvialis, 4 μg / mL-20 μg / mL of ergothioneine, 4 μg / mL-20 μg / mL of Houttuynia cordata, 25 μg / mL-250 μg / mL of non-denatured type II collagen, and 5 μg / mL-50 μg / mL of sodium hyaluronate.

[0048] In some preferred embodiments, the functional composition for improving bone and joint health comprises, at concentrations thereof, 100 μg / mL-500 μg / mL of elastin peptide, 4 μg / mL-20 μg / mL of Haematococcus pluvialis and 4 μg / mL-20 μg / mL of ergothioneine, 4 μg / mL-20 μg / mL of Houttuynia cordata, 200 μg / mL-250 μg / mL of non-denatured type II collagen and 5 μg / mL-50 μg / mL of sodium hyaluronate.

[0049] The functional composition for improving bone and joint health provided in this application uses elastin peptides, Haematococcus pluvialis, Houttuynia cordata, ergothioneine, etc., which are all of natural origin and have good biocompatibility. By scientifically combining the raw materials, they synergistically promote the production of glycosaminoglycans in chondrocytes and osteocalcin in osteoblasts, thereby significantly enhancing the protective effect of the composition on joint and bone health. It is also highly safe and has few side effects, and can be used as an alternative or supplement to traditional treatment drugs.

[0050] Secondly, this application also provides a conditioning agent comprising the functional composition provided in the first aspect that improves bone and joint health.

[0051] In some embodiments, the conditioning agent may be applied topically and / or orally.

[0052] In some embodiments, the dosage form of the conditioning agent includes suspensions, granules, capsules, powders, tablets, emulsions, solutions, pellets, injections, aerosols, gels, patches, dressings, drops, or liniments.

[0053] The conditioning agent provided in this application has excellent therapeutic and / or preventive effects on bone diseases, and has good efficacy against osteoarthritis and bone loss diseases, and is not limited to use as a drug or nutritional supplement; at the same time, the conditioning agent can be prepared into different dosage forms according to actual needs, which is convenient for joint and bone protection and provides a more convenient and effective treatment method.

[0054] Thirdly, this application also provides the use of functional compositions or conditioning agents in the preparation of formulations for the treatment or prevention of bone diseases, wherein the functional compositions include the functional compositions provided in the first aspect that improve bone and joint health, and the conditioning agents include the conditioning agents provided in the second aspect.

[0055] In some embodiments, the skeletal disease includes bone disease and / or joint disease.

[0056] In some embodiments, the bone disease includes bone loss disorders and / or bone metabolism disorders. As a non-limiting example, the bone loss disorder includes osteoporosis.

[0057] In some embodiments, the joint disease includes osteoarthritis. As a non-limiting example, the osteoarthritis includes osteoarthritis and / or articular cartilage degeneration.

[0058] For experimental parameters not specified in the following specific embodiments, please refer to the guidelines given in this application document first, or refer to experimental manuals or other experimental methods known in the art, or refer to the experimental conditions recommended by the manufacturer.

[0059] The raw materials and reagents involved in the following specific embodiments can be obtained commercially or prepared by those skilled in the art using known methods.

[0060] The specific sources and types of raw materials and cells involved in the specific embodiments of this application are as follows:

[0061] Elastin peptides were purchased from Hainan Huayan Collagen Technology Co., Ltd.; Haematococcus pluvialis was purchased from Dalian Yinuo; Houttuynia cordata powder was purchased from Betalife Biotechnology Co., Ltd.; and undenatured type II collagen (UC-II) was purchased from Lonza. All other chemical reagents were standard reagents.

[0062] Example 1 Functional Composition

[0063] The functional composition formulations provided in this embodiment are shown in Table 1:

[0064] Table 1: Formulation of Functional Compositions

[0065]

[0066] The above 12 formulations were mixed with complete cell culture medium according to the formulation amounts to prepare functional compositions.

[0067] Experimental Example 1: Effects of Functional Compositions on Cell Viability

[0068] In this experiment, immortalized human chondrocytes (purchased from Zhejiang Meisen Cell Technology Co., Ltd.) and human osteoblast cell line hFOB1.19 (purchased from Shanghai Qingqi Biotechnology Development Co., Ltd.) were used as test subjects to detect the effects of different drug combinations on cell viability. The cell viability CCK8 assay kit was purchased from Dojin Chemical Co., Ltd., Japan.

[0069] The specific experimental steps are as follows: Chondrocytes in the logarithmic growth phase were collected and digested. The chondrocytes were then used to prepare a chondrocyte suspension in DMEM / F-12 complete medium (purchased from Zhejiang Meisen Cell Technology Co., Ltd., catalog number CTCC-002-004) containing 10% fetal bovine serum and 1% penicillin and streptomycin. Osteoblasts were seeded into 96-well plates using DMEM complete medium (purchased from Gibco, catalog number 3144500), with a cell count of 1.1 × 10⁶ cells per well. 4 / well. Cells were cultured overnight at 37°C in a 5% CO2 incubator. When cell confluence was approximately 80%, the functional composition was diluted with complete culture medium according to the concentrations specified in Table 1. A blank control group containing only culture medium was also included. Cells treated with the functional composition were placed back into the incubator for another 24 hours. The original culture medium was replaced with medium containing 10% CCK-8. The 96-well plate was then placed in the incubator for 30 minutes, and the OD value of each well was measured at 450 nm. Six replicates were performed for each concentration. The cell proliferation and survival rate of different drugs were calculated according to formula (1).

[0070] (1)

[0071] The results obtained using the above testing method are shown in Table 2:

[0072] Table 2: Toxicity of Functional Compositions on Human Cartilage and Osteoblasts

[0073]

[0074] The results are shown in Table 2. The functional compositions of the 12 formulations showed no toxic effects on human chondrocytes and osteoblasts.

[0075] Experimental Example 2: Effect of Functional Compositions on Glycosaminoglycans in a Chondrocyte Osteoarthritis Model

[0076] In this study, immortalized human chondrocytes were used as the test subjects to investigate the effects of different drug combinations on glycosaminoglycans in an etoposide (purchased from MCE, catalog number HY-13629)-induced osteoarthritis model. The glycosaminoglycan assay kit was purchased from Shanghai Keabob Biotechnology Co., Ltd., catalog number CB11354-Hu.

[0077] The specific experimental steps are as follows: Human chondrocytes were divided into groups of 5 × 10⁻⁶ cells. 6 Cells were seeded in 6-well plates and cultured overnight at 37°C with 5% CO2. When cell confluence reached approximately 80%, drug treatment was administered. The experiment included a blank control group, a model group (etoposide, 25 mM), a positive control group (glucosamine, 1 mM), and 12 functional composition treatment groups as shown in Table 1. After 24 hours of incubation, the cell supernatant was collected and centrifuged at 2000-3000 rpm for 20 minutes. The supernatant was then used as the test sample.

[0078] The concentration of glycosaminoglycans was detected using an enzyme-linked immunosorbent assay (ELISA). For detailed procedures, please refer to the instruction manual.

[0079] The results obtained using the above testing method are shown in Table 3:

[0080] Table 3: Effects of functional compositions on glycosaminoglycan concentration in chondrocytes

[0081]

[0082] As shown in Table 3, etoposide induction of chondrocytes significantly reduced glycosaminoglycan concentration, while glycosaminoglycan production significantly increased in the positive control group, indicating the successful establishment of the osteoarthritis model. Formulas 1-9 enhanced glycosaminoglycan production under these model conditions, with formulas 1-4 showing the most significant effect. In contrast, formulas 1-3 had a relatively weaker effect on glycosaminoglycan production compared to formulas 1-9. Therefore, the formulas provided in this application have a better effect on improving osteoarthritis inflammation.

[0083] Experimental Example 3: Effect of Functional Compositions on Osteocalcin in an Osteoblast Osteoporosis Model

[0084] In this experiment, the human osteoblast cell line hFOB1.19 (purchased from Shanghai Qingqi Biotechnology Development Co., Ltd.) was used as the test subject to detect the effects of different drug combinations on osteocalcin in a D-galactose (purchased from Aladdin, catalog number G100369)-induced osteoporosis model. The human osteocalcin assay kit was purchased from Shanghai Keabob Biotechnology Co., Ltd., catalog number CB10653-Hu.

[0085] The specific experimental steps are as follows: Human osteoblasts were divided into groups of 6 × 10⁻⁶ cells. 6 Cells were seeded in 6-well plates and cultured overnight at 37°C with 5% CO2. When cell confluence was approximately 80%, drug treatment was administered. The experiment included a blank control group, a model group (200 mM D-galactose), a positive control group (10 μM teriparatide, purchased from MCE, catalog number HY-P0059), and functional composition treatment groups as shown in Table 1. After 24 hours, cell supernatant was collected and centrifuged at 2000-3000 rpm for 20 minutes. The supernatant was used as the test sample.

[0086] The osteocalcin concentration was detected using an enzyme-linked immunosorbent assay (ELISA). See the instruction manual for detailed procedures.

[0087] The results obtained using the above testing methods are shown in Table 4:

[0088] Table 4: Effects of functional compositions on osteocalcin concentration in osteocytes

[0089]

[0090] As shown in Table 4, D-galactose-induced osteoblasts significantly reduced osteocalcin concentration, while osteocalcin production was significantly increased in the positive control group, indicating the successful establishment of the osteoporosis model. Formulas 1-9 significantly enhanced osteocalcin production under these model conditions. In contrast, formulas 1-3 showed no effect on osteocalcin concentration, indicating that they did not significantly improve osteoporosis. Therefore, the first and second active ingredients in the formulas provided in this application exhibit a synergistic effect, which can improve osteoporosis and other bone diseases.

[0091] In summary, based on the results in Tables 3 and 4, this application achieves synergistic effects among its active components through scientific formulation. This synergistically promotes the production of glycosaminoglycans in chondrocytes and osteocalcin production in osteoblasts, demonstrating good efficacy in the treatment and prevention of bone diseases, particularly achieving simultaneous improvement in both bone and joint diseases. Furthermore, the raw materials in the formulation provided by this application are naturally sourced, safe, biocompatible, and have no significant side effects, offering a class of drugs or alternatives for the treatment and prevention of bone diseases.

[0092] The technical features of the above embodiments can be combined in any way. For the sake of brevity, not all possible combinations of the technical features in the above embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.

[0093] The embodiments described above are merely illustrative of several implementation methods of this application, and while the descriptions are relatively specific and detailed, they should not be construed as limiting the scope of the invention patent. It should be noted that those skilled in the art can make various modifications and improvements without departing from the concept of this application, and these all fall within the protection scope of this application. Therefore, the protection scope of this patent application should be determined by the appended claims.

Claims

1. A functional composition for improving bone and joint health, characterized in that, The active components of the functional composition for improving bone and joint health consist of a first active component and a second active component; Based on the concentration in the functional composition for improving bone and joint health, the first active component is 100 μg / mL-500 μg / mL of elastin peptide, 4 μg / mL-20 μg / mL of Haematococcus pluvialis, and 4 μg / mL-20 μg / mL of ergothioneine. Based on the concentration in the functional composition for improving bone and joint health, the second active component is houttuynia cordata 4 μg / mL-20 μg / mL and non-denatured type II collagen 25 μg / mL-250 μg / mL.

2. A functional composition for improving bone and joint health, characterized in that, The active components of the functional composition for improving bone and joint health consist of a first active component, a second active component, and a third component; Based on the concentration in the functional composition for improving bone and joint health, the first active component is 100 μg / mL-500 μg / mL of elastin peptide, 4 μg / mL-20 μg / mL of Haematococcus pluvialis, and 4 μg / mL-20 μg / mL of ergothioneine. Based on the concentration in the functional composition for improving bone and joint health, the second active component is houttuynia cordata 4 μg / mL-20 μg / mL and non-denatured type II collagen 25 μg / mL-250 μg / mL; The third active component is sodium hyaluronate at a concentration of 5 μg / mL to 50 μg / mL in the functional composition for improving bone and joint health.

3. A functional composition for improving bone and joint health, characterized in that, The active components of the functional composition for improving bone and joint health consist of a first active component, a second active component, and a third active component; Based on the concentration in the functional composition for improving bone and joint health, the first active component is 100 μg / mL of elastin peptide, 4 μg / mL of Haematococcus pluvialis and 20 μg / mL of ergothioneine. The second active ingredient is 20 μg / mL of houttuynia cordata, based on the concentration in the functional composition that improves bone and joint health. The third active component is sodium hyaluronate at a concentration of 50 μg / mL in the functional composition for improving bone and joint health.

4. A conditioning agent, characterized in that, The conditioning agent includes the functional composition according to any one of claims 1 to 3 that improves bone and joint health.

5. The conditioner according to claim 4, characterized in that, The application of the conditioning agent includes external and / or internal use; and / or, the dosage form of the conditioning agent includes suspension, granules, capsules, powders, tablets, emulsions, solutions, pellets, injections, aerosols, gels, patches, dressings, drops, or liniments.

6. The use of a functional composition or conditioning agent in the preparation of an agent for the treatment or prevention of bone diseases, characterized in that, The functional composition includes the functional composition for improving bone and joint health as described in any one of claims 1 to 3, and the conditioning agent includes the conditioning agent as described in claim 4 or 5.

7. The use of the functional composition or conditioning agent according to claim 6 in the preparation of formulations for the treatment or prevention of bone diseases, characterized in that, The skeletal diseases include bone diseases and / or joint diseases.

8. The use of the functional composition or conditioning agent according to claim 7 in the preparation of formulations for the treatment or prevention of bone diseases, characterized in that, The bone diseases include bone loss diseases; and / or, the joint diseases include osteoarthritis.

Images